InvestorsHub Logo
Followers 0
Posts 1503
Boards Moderated 0
Alias Born 09/02/2012

Re: None

Thursday, 07/03/2014 11:57:58 AM

Thursday, July 03, 2014 11:57:58 AM

Post# of 2420
ARCA Biopharma: An Undervalued Biotech With A Bright Future
Jul. 3, 2014 10:50 AM ET | 3 comments | About: ARCA biopharma, Inc. (ABIO)
Disclosure: The author is long ABIO. (More...)
Summary

ARCA biopharma is on track with its second Phase II trial for a genetically targeted treatment of atrial fibrillation.
ARCA biopharma has close to $22 million cash on hand, which represents 70% of the company's market cap and a cash runway through 2015.
With a $31 million market cap, 74% success rate based on prior trial data, and an indication with over 30 million patients worldwide, ARCA biopharma appears substantially undervalued.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABIO News